What is Genomic Profiling (NGS)?
Next-Generation Sequencing (NGS) analyzes hundreds of cancer genes simultaneously from a tumor biopsy or liquid biopsy (blood). It identifies actionable mutations, resistance mechanisms, tumor mutational burden (TMB), and microsatellite instability (MSI) to guide precision therapy.
NGS identifies targetable mutations in 60–70% of solid tumors. Guides immunotherapy eligibility (PD-L1, TMB-H, MSI-H) and targeted therapy selection (EGFR, ALK, KRAS, HER2, BRAF, RET, MET).
What Does the Panel Analyze?
- 324–500 cancer-related genes (FoundationOne, MSK-IMPACT equivalent panels)
- Tumor Mutational Burden (TMB)
- Microsatellite Instability (MSI)
- Copy Number Variations (CNV)
- Gene fusions and rearrangements
- Germline vs somatic variant classification
Liquid Biopsy Option
For patients unable to undergo tissue biopsy, liquid biopsy (ctDNA) from a simple blood draw can identify the same actionable mutations — especially valuable for monitoring treatment response and detecting resistance.
Turnaround Time and Cost in Istanbul
Results in 10–14 business days. Istanbul cost: $1,500–3,500 depending on panel size. USA equivalent: $3,500–7,000. Same laboratory standards (CAP/CLIA certified partners).
How Results Guide Treatment
After analysis, our oncology board reviews your NGS report and prepares a personalized treatment recommendation covering approved therapies, clinical trials, and investigational agents matching your mutation profile.